BioMarin’s Gene Therapy Roctavian More Cost-Effective in Hemophilia A than Genentech and Chugai’s Hemlibra

September 26, 2022

ICER has released a draft report that indicates Roctavian, BioMarin’s new gene therapy for hemophilia A, will beat the current antibody-based therapeutic Hemlibri. Unlike Hemlibri, which is a prophylactic, Roctavian restores the gene lacking in hemophilia A, factor VIII. The organization predicts that the one-time price of $2.5 million for Roctavian will be substantially lower than that of 12 years worth of Hemlibra at $640,000 annually.

According to Steve Bryson, PhD, “Based on these assumptions, ICER estimated more than $4 million would be saved using Roctavian instead of Hemlibra per patient over a lifetime. Gene therapy also was associated with slightly fewer bleeds and higher quality-adjusted life years (QALY) — a measure of disease burden, including both the quality and the quantity of life lived; one QALY corresponds to one year of perfect health.”

To read more, click here.